IGM-6268 is an IgM version of an anti-SARS-CoV-2 IgG monoclonal antibody and is being developed as an intranasally administered agent for the treatment and prevention of COVID-19.
In preclinical studies, IGM-6268 has been shown to be highly effective in preventing and treating COVID-19 after intranasal administration. Due to its ability to bind to SARS-CoV-2 with greater strength, IGM-6268 offers advantages over corresponding IgG antibodies, including 100x greater neutralizing potency and greater ability to effectively neutralize certain Variants of Concern and Variants of Interest, such as the Delta variant, as compared with an IgG antibody with the same binding units to the virus.